JP4577985B2 - ジフェニルエチレン化合物の新規な複素環類似体 - Google Patents

ジフェニルエチレン化合物の新規な複素環類似体 Download PDF

Info

Publication number
JP4577985B2
JP4577985B2 JP2000547978A JP2000547978A JP4577985B2 JP 4577985 B2 JP4577985 B2 JP 4577985B2 JP 2000547978 A JP2000547978 A JP 2000547978A JP 2000547978 A JP2000547978 A JP 2000547978A JP 4577985 B2 JP4577985 B2 JP 4577985B2
Authority
JP
Japan
Prior art keywords
linear
compound
substituted
independently
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000547978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002514598A (ja
JP2002514598A5 (enExample
Inventor
パルサ ネオギー
ビシュワジト ナグ
サチアナラヤナ メディチェルラ
ディベンドラナタ デイ
Original Assignee
カリックス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/074,925 external-priority patent/US6245814B1/en
Application filed by カリックス セラピューティックス インコーポレイテッド filed Critical カリックス セラピューティックス インコーポレイテッド
Publication of JP2002514598A publication Critical patent/JP2002514598A/ja
Publication of JP2002514598A5 publication Critical patent/JP2002514598A5/ja
Application granted granted Critical
Publication of JP4577985B2 publication Critical patent/JP4577985B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2000547978A 1998-05-08 1999-05-07 ジフェニルエチレン化合物の新規な複素環類似体 Expired - Fee Related JP4577985B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/074,925 1998-05-08
US09/074,925 US6245814B1 (en) 1998-05-08 1998-05-08 Diphenylethylene compounds
US09/287,237 1999-04-06
US09/287,237 US6331633B1 (en) 1998-05-08 1999-04-06 Heterocyclic analogs of diphenylethylene compounds
PCT/US1999/009982 WO1999058127A1 (en) 1998-05-08 1999-05-07 Novel heterocyclic analogs of diphenylethylene compounds

Publications (3)

Publication Number Publication Date
JP2002514598A JP2002514598A (ja) 2002-05-21
JP2002514598A5 JP2002514598A5 (enExample) 2006-06-29
JP4577985B2 true JP4577985B2 (ja) 2010-11-10

Family

ID=26756222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000547978A Expired - Fee Related JP4577985B2 (ja) 1998-05-08 1999-05-07 ジフェニルエチレン化合物の新規な複素環類似体

Country Status (13)

Country Link
US (1) US6331633B1 (enExample)
EP (1) EP1007039B1 (enExample)
JP (1) JP4577985B2 (enExample)
KR (1) KR100595919B1 (enExample)
CN (1) CN1151139C (enExample)
AT (1) ATE260906T1 (enExample)
AU (1) AU751235C (enExample)
CA (1) CA2295599C (enExample)
DE (1) DE69915223T2 (enExample)
DK (1) DK1007039T3 (enExample)
ES (1) ES2216513T3 (enExample)
PT (1) PT1007039E (enExample)
WO (1) WO1999058127A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041941B2 (en) 1997-04-07 2006-05-09 Patented Medical Solutions, Llc Medical item thermal treatment systems and method of monitoring medical items for compliance with prescribed requirements
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6515003B1 (en) 1999-08-31 2003-02-04 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of diabetes and other diseases
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
JP2003520226A (ja) 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
PL373912A1 (en) 2001-03-07 2005-09-19 Incyte San Diego, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
WO2002072543A2 (en) 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Rxr activating molecules
EP1435894A4 (en) 2001-07-23 2005-07-06 Galileo Pharmaceuticals Inc CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS AND METHOD
KR100468429B1 (ko) * 2001-09-07 2005-01-27 주식회사 엔바이오테크놀러지 알파-글루코시다제 저해활성이 있는 소나무 추출물 및 그추출방법
WO2003043998A1 (en) 2001-11-15 2003-05-30 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2004033632A2 (en) 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
WO2005002672A2 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
AU2004312072B2 (en) 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CA2595486A1 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
WO2006126074A2 (en) * 2005-05-26 2006-11-30 Orchid Research Laboratories Limited Heterocyclic derivatives
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20090131420A1 (en) * 2005-10-07 2009-05-21 Pandey Surendrakumar S Novel Heterocyclic Analogs of Biphenyl Ethers
KR101016875B1 (ko) * 2006-06-23 2011-02-22 현대중공업 주식회사 밀폐형 방청유 도포장치
CN112209896B (zh) * 2019-07-10 2023-05-16 苏州泽璟生物制药股份有限公司 噻唑烷二酮衍生物以及包含其的药物组合物
KR20220029472A (ko) * 2020-08-28 2022-03-08 (주)셀로스바이오텍 신규 티오히단토인 유도체 및 이의 용도

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683009A (en) 1968-10-10 1972-08-08 Du Pont {60 , {62 -bis(trifluoromethyl) stilbenes
US3609183A (en) 1969-01-08 1971-09-28 Parke Davis & Co {60 -{8 {11 -(dimethylaminoalkyl)phenyl{9 -4-methoxy-{60 {40 -nitrostilbene compounds
US4312855A (en) 1970-11-16 1982-01-26 Colgate-Palmolive Company Compositions containing aminopolyureylene resin
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
US4284637A (en) 1978-03-09 1981-08-18 Mitsubishi Chemical Ind., Limited Pharmaceutically active 2-(4-aminobutoxy)stilbenes
JPS6045632B2 (ja) 1978-03-09 1985-10-11 三菱化学株式会社 ω−アミノアルコキシスチルベン類及びその酸付加塩
DE2832213A1 (de) 1978-07-21 1980-01-31 Bayer Ag Stilbenderivate, verfahren zu ihrer herstellung und ihre verwendung als insektizide
JPS5629548A (en) 1979-08-16 1981-03-24 Mitsubishi Chem Ind Ltd Omega-aminoalkoxystilbenes and their acid addition salts
FR2562539B1 (fr) 1984-04-06 1987-04-17 Chauvin Blache Lab Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands
US4716905A (en) 1985-09-25 1988-01-05 Fluorochrome, Inc. Method of retrograde fluorescent labeling of neurons
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
GB8716650D0 (en) 1987-07-15 1987-08-19 Ici Plc Use of olefinic compounds
US5250562A (en) 1988-02-24 1993-10-05 Hoffmann-La Roche Inc. Stilbene derivatives
CA1340955C (en) 1988-02-24 2000-04-11 Michael Klaus Stilbene derivatives
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
DE3926148A1 (de) 1989-08-08 1991-02-28 Basf Ag Diarylacetylene, ihre herstellung und verwendung
US5189056A (en) 1989-12-19 1993-02-23 University Of North Carolina At Chapel Hill Protection of moist stratified squamous epithelia against damage from noxious luminal agents
US5162337A (en) 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
DK0498095T3 (da) 1991-02-05 1995-06-19 Merrell Dow Pharma Sulfoniske stilbenderivater til behandling af virussygdomme
CH683151A5 (de) 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
US5171753A (en) 1991-05-15 1992-12-15 A. H. Robins Company, Incorporated Derivatives of 2-amino-1-phenylethanol having antiulcer activity
ES2159282T3 (es) 1991-11-07 2001-10-01 Nanotronics Inc Hibridacion de polinucleotidos conjugados con cromoforas y fluoroforos con el fin de generar sistemas de transferencia de energia de donador a donador.
US5246936A (en) 1991-12-20 1993-09-21 American Cyanamid Company Methods and compositions containing pesticides and stilbene compounds for enhanced pesticidal activity
NO302471B1 (no) * 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5314693A (en) 1992-02-07 1994-05-24 Kioritz Corporation Pest control chemicals against pine wood nematodes
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
DE69418947T2 (de) 1993-03-10 1999-12-23 Morinaga Milk Industry Co. Ltd., Tokio/Tokyo Stilbenderivate und analoga sowie deren anwendung
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
IT1264988B1 (it) 1993-12-14 1996-10-17 Sigma Prod Chim Composizioni cosmetiche e dermatologiche per la protezione da radiazioni uv contenenti derivati dallo stilbene
TW308598B (enExample) 1994-01-14 1997-06-21 Hoffmann La Roche
JPH08143566A (ja) * 1994-11-25 1996-06-04 Terumo Corp キナゾリン誘導体及びそれを含有する医薬組成物
US5559151A (en) 1994-11-30 1996-09-24 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
CA2174582A1 (en) 1995-05-05 1996-11-06 Alexander Chucholowski Sulphuric acid esters of amino-sugars
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5770620A (en) 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes

Also Published As

Publication number Publication date
KR100595919B1 (ko) 2006-07-03
EP1007039A4 (en) 2002-05-22
PT1007039E (pt) 2004-07-30
AU3974199A (en) 1999-11-29
US6331633B1 (en) 2001-12-18
EP1007039A1 (en) 2000-06-14
JP2002514598A (ja) 2002-05-21
ATE260906T1 (de) 2004-03-15
KR20010021615A (ko) 2001-03-15
DE69915223D1 (de) 2004-04-08
DK1007039T3 (da) 2004-07-12
CA2295599A1 (en) 1999-11-18
DE69915223T2 (de) 2005-01-27
WO1999058127A1 (en) 1999-11-18
CN1151139C (zh) 2004-05-26
EP1007039B1 (en) 2004-03-03
AU751235C (en) 2004-06-24
HK1028348A1 (en) 2001-02-16
AU751235B2 (en) 2002-08-08
CA2295599C (en) 2009-01-20
ES2216513T3 (es) 2004-10-16
CN1273528A (zh) 2000-11-15

Similar Documents

Publication Publication Date Title
JP4577985B2 (ja) ジフェニルエチレン化合物の新規な複素環類似体
KR101962209B1 (ko) 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도
US4613593A (en) Therapeutic and preventive agent containing dolichol
JP2022169806A (ja) Ａｃｃ阻害剤を含む併用療法
JP2020505331A (ja) 新規フェニル誘導体
JP2002516318A (ja) ジペプチジル・ペプチダーゼｉｖの新規エフェクター
KR20080106455A (ko) 대사장애의 조합치료
TW200918049A (en) Compounds useful as medicaments
US6525093B1 (en) Compounds to treat diabetes and associated conditions
WO2005123132A2 (en) Use of liver-selective glucokinase activators
KR101391905B1 (ko) 물질대사 장애의 치료용 화합물
JP3944393B2 (ja) インスリン抵抗性および糖尿病のための、コリン塩基とコハク酸とを含む相乗効果のある組成物
Rosen et al. Corticosteroids and transaminase activity III. A relationship between changes in alanine transaminase activity and the growth of Walker carcinosarcoma 256
CN1358096A (zh) 糖尿病治疗剂
US4791105A (en) Therapeutic and preventive agent containing dolichol
US4603126A (en) Therapeutic and preventive agent containing dolichol
EP0149847A2 (en) Therapeutic and preventive agent containing dolichol
JP2021526552A (ja) 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸
US4599328A (en) Therapeutic and preventive agent containing dolichol
HK1028348B (en) Novel heterocyclic analogs of diphenylethylene compounds
WO2025158806A1 (ja) 代謝機能不全に関連した脂肪性肝疾患の予防又は改善剤
CN117653642A (zh) 格列本脲促进nad+水平的用途
HK1045121B (en) Remedies for diabetes
JPH0459728A (ja) 肝障害抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100729

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100824

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130903

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees